As of Wednesday, April 29, Intellia Therapeutics, Inc.’s NTLA share price has dipped by 6.01%, which has investors questioning if this is right time to buy.

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it ...

A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. 10 stocks ...

Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes directly inside the body – basically aiming to fix diseases at their root with a ...

Intellia Therapeutics (NASDAQ:NTLA) jumped about 25%on Monday as investors positioned for data from its Phase 3 HAELO study of lonvoguran ziclumeran, a gene-editing treatment for hereditary angioedema ...

Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John Leonard, MD, announced that, given greater-than-expected patient enrollment in a Phase III trial assessing ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other ...

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene ...